Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C study.
Yu Jun WongSally TranChung-Feng HuangYao-Chun HsuCarmen PredaHidenori ToyodaJoanne LiuDae Won JunCharles LandisDaniel Q HuangAndrei GilaLivia NegoitaSatoshi YasudaCheng-Hao TsengPei-Chien TsaiHaruki UojimaAkito NozakiMakoto ChumaMasanori AtsukawaMasatoshi IshigamiNorio ItokawaEtsuko IioCarla Pui-Mei LamTsunamasa WatanabeAkira AsaiKeisuke YokohamaHiroshi AbeMasaru EnomotoNorifumi KawadaAkihiro TamoriDong Hyun LeeMi Jung JunSon DoDang K H VoLi LiuJunyi LiFanpu JiWenjun WangYu LiXiaozhong WangFen GuoQiang XuLiang JingQing YeHongying PanJiaJie ZhangXie WenQi WangHong RenDachuan CaiJia ShangJunping LiuChengzheng LuWenqian ZangJia LiJunqi NiuMingyuan ZhangChao WuRui HuangMayumi MaedaAkiko NakanishiMing-Lun YehWan-Long ChuangJee-Fu HuangChiaYen DaiToru IshikawaKoichi TakaguchiTomonori SenohHuy N TrinhHirokazu TakahashiYuichiro EguchiSabrina Xin Zi QuekHiroaki HagaEiichi OgawaGrace WongMaria ButiShinya FukunishiYoshiyuki UenoMan-Fung YuenYasuhito TanakaSeng Gee LimRamsey CheungMing-Lung YuMindie H NguyenPublished in: Hepatology international (2023)
Tolerability and treatment outcomes were not significantly different in advanced HCV cirrhosis treated with PI-based (vs. non-PI) DAA up to CTP-B or MELD score of 15. Safety of PI-based DAA in those with CTP-C or MELD beyond 15 awaits further data.